This article refers to 'Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial', by J.-S. Hulot et al., published in this issue on pages 1534-1541.